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Hypertrophic cardiomyopathy (HCM) is entering a phase of intense translational research that holds promise of major advances in
disease-specific pharmacological therapy. For over 50 years, however, HCM has largely remained an orphan disease, and patients are
still treated with old drugs developed for other conditions. While judicious use of the available armamentarium may control the clinical
manifestations of HCM in most patients, specific experience is required in challenging situations, including deciding when not to treat.
The present review revisits the time-honoured therapies available for HCM, in a practical perspective reflecting real-world scenarios.
Specific agents are presented with doses, titration strategies, pros and cons. Peculiar HCM dilemmas such as treatment of dynamic outflow
obstruction, heart failure caused by end-stage progression and prevention of atrial fibrillation and ventricular arrhythmias are assessed. In
the near future, the field of HCM drug therapy will rapidly expand, based on ongoing efforts. Approaches such as myocardial metabolic
modulation, late sodium current inhibition and allosteric myosin inhibition have moved from pre-clinical to clinical research, and reflect a
surge of scientific as well as economic interest by academia and industry alike. These exciting developments, and their implications for future
research, are discussed.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the most common genetic
heart disease, characterized by complex pathophysiology, het-
erogeneous morphology, and variable clinical manifestations over
time.1–4 Initially perceived as a rare and malignant disease, the
spectrum of HCM has subsequently expanded, as new concepts
have emerged regarding its true prevalence and clinical profile.3,5
The disease is known to range from the severe manifestations
of early descriptions, to the absence of clinical and morpho-
logic expression, including lack of left ventricular (LV) hyper-
trophy, in genotype-positive individuals.6,7 To date, none of the
available pharmacological agents have been shown to modify dis-
ease development or outcome in HCM patients,8,9 with the possi-
ble exception of diltiazem in preventing LV remodelling.10 The only
interventions believed to have an impact on long-term prognosis
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. are surgical myectomy and the implantable cardiac defibrillator
(ICD).8 Nevertheless, pharmacological therapy plays a very impor-
tant role in restoring quality of life and reducing the risk of
disease-related complications. The main goals of pharmacological
therapy in HCM include control of symptoms and exercise lim-
itation, abolition or reduction of dynamic intraventricular gradi-
ents, treatment of LV dysfunction and heart failure (HF), control of
atrial fibrillation (AF) and ventricular arrhythmias, and prevention
of cardioembolism.
After more than 50 years from the first reported case of HCM,
only about 2000 patients have been randomized in clinical tri-
als evaluating the efficacy of drug treatments for HCM.8 There-
fore, international guidelines are largely based on the opinion of
experts11,12 and the scientific community is still waiting for robust
evidence and disease-specific treatment options. In this paper, we
will review the indications of individual agents in the management
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Figure 1 Clinical scenarios and symptoms associated with hypertrophic cardiomyopathy (HCM) and representation of current pharmaco-
logical (yellow balloons) and non-pharmacological treatments (orange balloons). ACEi, angiotensin-converting enzyme inhibitors; AF, atrial
fibrillation; ARBs, angiotensin receptor blockers; CRT, cardiac resynchronization therapy; HTx, heart transplantation; ICD, implantable car-
diac defibrillator; LVAD, left ventricular assist device; LVOTO, left ventricular outflow tract obstruction; MRAs, mineralocorticoid receptor
antagonists; NOAC, novel oral anticoagulant; NSVT, non-sustained ventricular tachycardia; OAC, oral anticoagulant; SVT, sustained ventricular
tachycardia.
of HCM in the context of its complex pathophysiology, provide
practical therapeutic considerations in the light of the 2014 Euro-
pean Society of Cardiology (ESC) guidelines,11 and address promis-
ing new approaches currently under scrutiny.
Clinical profiles and genesis
of symptoms
Hypertrophic cardiomyopathy may be associated with a normal
life expectancy and a very stable clinical course. About a third of
patients develop HF, related to dynamic LV outflow tract obstruc-
tion (LVOTO). In addition, 5–15% show progression to either
the restrictive or the dilated hypokinetic evolution of HCM, both
of which may require evaluation for cardiac transplantation.13,14
Patients with HCM can remain asymptomatic for their entire
lifetime.11–13,15 However, symptoms are common (Figure 1) and
often insidious: for example, reduced exercise tolerance may
not be subjectively perceived as abnormal when present from a
very young age. Furthermore, quality of life may be subtly but .
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.. significantly impaired by psychological issues, iatrogenic symptoms,
and lifestyle restrictions.11
Dyspnoea is common, and reflects high LV filling pressure,
diastolic dysfunction or afterload mismatch with mitral regurgi-
tation secondary to LVOTO.11,15 In addition, paroxysmal AF has
been associated with impaired cardiac reserve, defined as reduced
exercise capacity and maximal oxygen consumption.16,17 In patients
with LVOTO, symptoms are typically variable over time, exacer-
bated by dehydration, meals, alcohol, use of vasodilators, and squat-
ting. Less frequently, patients report nocturnal orthopnoea, either
the consequence of congestive HF or bradyarrhythmias (AF with
slow ventricular response or sinoatrial dysfunction).
Angina affects about 30% of symptomatic adults and is often
atypical, occurring at rest and/or postprandially.18 Angina is typically
related to microvascular dysfunction and increased LV wall stress
caused by LVOTO, in the absence of epicardial coronary lesions.
When typical, angina should prompt specific investigations to
exclude myocardial bridging of the left anterior descending artery
in children and atherosclerotic coronary artery disease in older
patients.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
© 2016 The Authors
European Journal of Heart Failure © 2016 European Society of Cardiology
Pharmacological treatment of HCM 3
Beta-blockers
Verapamil/diltiazem
Dysopiramide
Cybenzoline
Allosteric Myosin Inihibitors
Gene+ Pheno -
Asymptomatic HCM
Symptomatic 
non-obstructive HCM
Symptomatic 
Obstructive HCM
Adverse remodelling
End-stage
Diltiazem
Valsartan
Beta-blockers
Losartan/valsartan
Eleclazine
Allosteric Myosin Inihibitors
Perhexiline
Ranolazine
Eleclazine
Beta-blockers
Verapamil/diltiazem
Beta-blockers
ACEi/ARBS
MRA
Diuretics
Perindopril / 
Indapamide
Figure 2 Stages of hypertrophic cardiomyopathy (HCM) and relevant medical treatments. Hatched black arrows reflect potential transitions
from one stage to another. Approved medical interventions in specific stage of disease are in green. Drugs under investigation are in red. Pheno,
phenotype; HF, heart failure; ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; MRAs, mineralocorticoid
receptor antagonists.
Pre-syncope or syncope has been reported in about 15–20%,
and is generally attributed to sustained ventricular arrhythmias
or severe LVOTO, particular when associated with hypovolaemia
or occurring during or after effort.19 However, neurally medi-
ated syncope is common and should be excluded given its rad-
ically different prognostic value.20 Bradyarrhythmias caused by
sinoatrial or atrioventricular (AV) block are more common than
generally perceived, and may cause syncope even in very young
HCM patients.21 Finally, in a small minority of patients, sudden
cardiac death (SCD) may represent the first manifestation of
disease.22,23
Treatment of dynamic left
ventricular outflow tract
obstruction
Left ventricular outflow tract obstruction is a complex pathophys-
iological hallmark of HCM, caused by systolic anterior movement
of anomalous mitral valve leaflets, contacting the septum at the
subaortic level; less frequently, dynamic gradients may occur at the
mid-ventricular level. Classically, LVOTO is defined by peak gradi-
ents exceeding 30mmHg at rest or 50mmHg during exercise, and
is associated with unfavourable prognosis because of HF-related
complications.24 Moreover, a significant association with SCD has
been reported.24,25 In the presence of severe, drug-refractory
symptoms, LVOTO represents an indication for surgical myectomy
or percutaneous alcohol septal ablation26 [Class I, level of evidence
(LOE) B in the 2014 ESC guidelines).11 However, pharmacological
treatment represents the first approach to all obstructive patients ..
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.. and, if properly used, may be effective in controlling gradients and
symptoms for years (Figure 2).
Beta-blockers are the most popular and effective agents
employed.11 The classic studies by Braunwald on propra- AQ3
nolol date back to the 1950s, showing impressive gradient
and symptoms reduction in the acute setting.8,27 Presently,
atenolol (50–200mg/day), nadolol (40–160mg/day), bisoprolol AQ4
(5–10mg/day), and metoprolol (100–200mg/day) are more
frequently used (Tables 1 and 2). High doses may be required,
and are usually well tolerated. However, side-effects (mostly
fatigue) should be carefully investigated in order to assess optimal
individual dose. At our institutions, nadolol is the drug of first
choice, in consideration of its good tolerability, favourable elec-
trophysiological profile, and potent effect of gradient and effective
24-h coverage.28 In our experience, titrating classic HCM therapy
with beta-blockers for dynamic obstruction is relatively easier
compared with patients with HF. Obstructive HCM is by definition
hyperdynamic and characterized by strong adrenergic drive. A
reasonable approach is to start with a quarter of a full dose of
beta-blockers (e.g. nadolol 20mg once daily, atenolol 25mg once AQ5
daily, metoprolol 25mg twice daily, or bisoprolol 2.5mg once
daily) and increase by the same amount every 1–2weeks to the
maximum tolerated dose (usually 80mg for nadolol and 100mg
for atenolol, 100mg twice daily for metoprolol, and 10mg twice
daily for bisoprolol, although it may be up to double that dose; see AQ6
Table 2). Beta-blockers may be titrated based on symptoms, heart
rate response, and blood pressure. Non-dihydropyridine calcium
channel blockers such as verapamil and diltiazem are considered
less effective,11 although they can be used in patients who are
intolerant of or have contraindications to beta-blockers.
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Table 2 Pharmacological indications to treat symptoms associated with hypertrophic cardiomyopathy (HCM) based
on 2014 European Society of Cardiology (ESC) and 2011 American College of Cardiology Foundation
(ACCF)/American Heart Association (AHA) guidelines
Clinical conditions associated with HCM ESC (2014) ACCF/AHA (2013)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dynamic left ventricular outflow tract obstruction
Beta-blockers I B I B
Verapamil/diltiazem (if beta-blockers contraindicated or not tolerated) I B IIa C (diltiazem) I B IIb C (diltiazem)
Disopyramide (in association with beta-blockers/verapamil) I B (IIb C if alone) IIa B
Oral diuretics (congestive symptoms despite the use of beta-blocker and/or verapamil) IIb C IIb C
Dyspnoea and angina in non-obstructive forms and progressive disease
Beta-blockers IIa C I B
Verapamil/diltiazem (if beta-blockers contraindicated or not tolerated) IIa C I B (only verapamil)
Oral diuretics (dyspnoea despite the use of beta-blocker and/or verapamil) IIa C IIa C
ACEi or ARBs (LVEF <50%) IIa C I B
MRA (LVEF <50% and persisting symptoms despite other HF treatments) IIa C –
Atrial fibrillation
Ventricular rate control
Beta-blockers (bisoprolol or carvedilol if LV systolic dysfunction) I C I C
Verapamil/diltiazem (only with preserved LVEF) I C I C
Digoxin (only with LVEF< 50%, no LVOTO and symptoms) IIb C –
Prevention of cardioembolic events
Oral anticoagulant agents (independent of CHA2DS2-VASc score/also after a single episode) I B I CAQ8
NOAC I B (as second option) I C (as second option)
Prevention of recurrences
–Amiodarone IIa B IIa B
–Sotalol IIb C
–Disopyramide (in presence of LVOTO in association with beta-blockers or verapamil) IIb C IIa B (also without LVOTO)
Ventricular arrhythmias
Reduction of the occurrence of NSTV
Amiodarone – –
Sotalol – –
Reduction of symptomatic VT or recurrent shocks (with ICD)
Amiodarone I C –
Beta-blockers I C –
ACEi, angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow
tract obstruction; MRA, mineralocorticoid receptor antagonist; NOAC, new oral anticoagulant agents; NSTV, non-sustained ventricular tachycardia.
Disopyramide (an antiarrhythmic class IA agent) can be used in
association with beta-blockers to improve symptoms and reduce
intraventricular gradients in patients with LVOTO by virtue of its
negative inotropic effect.11 Whereas beta-blockers are most effec-
tive on provokable LVOTO, disopyramide is the most effective
agent on resting obstruction.28 Efficacy and safety of disopyra-
mide has been demonstrated in a large multicentre registry.29,30
However, QT prolongation and its anticholinergic properties can
limit its use and impair compliance. The latter include xerostomy,
accommodation disturbances and, in men, lower urinary tract
symptoms/prostatism, which may be treated with low doses of
pyridostigmine.31 Moreover, disopyramide tends to lose its efficacy
over time. Therefore, in our experience, it often represents a phar-
macological ‘bridge’ to invasive septal reduction therapies, rather
than a long-term strategy. An electrocardiogram (ECG) should be
performed before initiation of the drug, to evaluate the corrected
QT (QTc) interval. Sustained-release 250mg tablets are the usual
choice, at a starting dose of 125mg twice a day. After the first
week, QTc is re-evaluated before disopyramide is titrated to the
full dose (250mg twice daily). It is essential to inform patients of .
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. the need to avoid concomitant therapy with other drugs associ-
ated with QTc prolongation; conditions that favour dehydration
or electrolyte imbalance should also be avoided. In patients who
are intolerant to disopyramide, cibenzoline has been employed by
Japanese authors, with beneficial effects on dynamic obstruction
and LV diastolic function.32 Serial evaluation of the resting outflow
gradient is important during the titration of the pharmacological
therapy, although drug titration should proceed if tolerated even
when systolic anterior movement is abolished, as obstruction is
likely to recur on effort. Exercise echocardiography should be per-
formed when the optimal regimen is reached, in order to exclude
residual provokable gradients.
In patients with LVOTO and concomitant disease requiring
pharmacological treatment, caution is required with vasodila-
tors and/or positive inotropic agents, because of the risk of
exacerbation of LVOTO; examples include phosphodiesterase
type 5 inhibitors for the treatment of erectile dysfunction,
methamphetamine for attention deficit hyperactivity disorder,
angiotensin-converting enzyme inhibitors (ACEi), or angiotensin
receptor blockers (ARBs) for treatment of concomitant systemic
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hypertension. Nevertheless, these drugs often seem well
tolerated.9,33,34
In the presence of asymptomatic patients with high resting or
provokable gradients, one should always question the true lack
of symptoms vs. lifestyle adaptation. These patients often have
demonstrable exercise limitation, which is exacerbated by meals.
Furthermore, severe gradients may be associated with haemody-
namic instability and abnormal blood pressure response on effort.
Based on these considerations, a course of pharmacological ther-
apy aimed at controlling outflow obstruction may lead to sub-
jective improvement even in ‘asymptomatic’ patients, and is likely
to provide greater haemodynamic balance during daily activity. If
well-tolerated and effective, treatment may be continued based on
patients’ preferences.
Prophylaxis for endocarditis is advised limited to patients with
LVOTO, when invasive medical procedures are required.35,36 How-
ever, risk is low, and neither the 2014 ESC guidelines nor the 2011
American College of Cardiology Foundation (ACCF)/American
Heart Association (AHA) guidelines on HCM specifically recom-
mended prophylaxis.11,12 However, these considerations should
be weighed against recent data suggesting an association between
decreased use of antibiotic prophylaxis in general cardiac patients
and an increase incidence of endocarditis, both in high- and low-risk
individuals.37
Treatment of non-obstructive
patients and progressive disease
In patients with preserved LV ejection fraction (LVEF), symp-
toms may be associated with diastolic dysfunction or microvascu-
lar ischaemia. However, the presence of severe refractory symp-
toms consistently elicited by exercise should raise suspicion of
labile obstruction, and be specifically investigated. Dyspnoea and
angina in non-obstructive patients can be usually controlled by
beta-blockers,11 employing the same agents used for LVOTO
although usually at lower doses. In patients with non-obstructive
HCM, titration of beta-blockers follows the aforementioned pat-
terns, although lower doses are generally required in view of a
less pronounced adrenergic drive. Symptomatic response and tol-
erability should drive titration, rather then specific instrumental
parameters. Diastolic indices, in particular, appear of little value in
this setting. Notably, in the small subset with end-stage disease,
whether owing to systolic dysfunction or restrictive evolution, the
armamentarium and modalities of classic HF is required. Titration
of beta-blockers should be more cautious in these patients because
of the fragile haemodynamic equilibrium. Diltiazem or verapamil
may be used as an alternative.11 Verapamil has been the most widely
applied therapy in HCM and, although a clear benefit in improve-
ment of functional capacity has never been demonstrated, it may
be effective in improving quality of life, likely because of its abil-
ity to slow heart rate and prolong LV ventricular filling time. The
dose ranges from 60mg twice daily to 240mg twice daily. Similar
effects are observed with diltiazem (dose range 120–360mg/day)
(Tables 1 and 2). ..
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.. In HCM patients with angina or atypical chest pain, no drug
has shown convincing efficacy in improving microvascular function.
In clinical practice, symptomatic relief may be obtained by classic
anti-ischaemic agents. The most effective are usually represented
by AV blocking drugs such as beta-blockers and verapamil. This is
consistent with an early observation by Cannon et al.38 showing
that high ventricular rates are associated with lactate release in
the coronary sinus in HCM patients (i.e. with ischaemia). In our
experience, ranolazine can also be very effective in controlling
chest pain,39 although individual response may be variable. Finally,
long-acting nitrates and dihydropyridines may be employed as
second-line agents, but are usually less effective unless there is
associated coronary artery disease.40
Up to 10–15% of patients with HCM develop signs and symp-
toms of HF despite preserved systolic function, with worsen-
ing diastolic indices subtended by extensive myocardial fibrosis
(Figures 2 and 3). Of these, about one-third develop frank LV
restriction and/or systolic dysfunction, evolving to refractory HF
and the so-called ‘end-stage’ of HCM.13,14 Standard HF therapy
should be systematically introduce below LVEF 50%,41 including
ACEi, ARBs, beta-blockers, mineral-corticoid receptor antagonists,
and loop diuretics (class IIa, LOE C).11 Considering that HCM is
generally characterized by a small LV cavity and supranormal sys-
tolic function, even LVEF values in the low-normal range should be
regarded with suspicion. Indeed, previous work from our groups
based on cardiac magnetic resonance (CMR) has shown that aver-
age LVEF in resting conditions exceeds 70% in HCM patients, and
that values in the 50–65% range may be already subtended by sig-
nificant amounts of myocardial fibrosis, suggesting that progression
towards end-stage disease may have begun.42 Thus, in selected
patients within this LVEF range, it is reasonable to consider HF
treatment with ACEi, ARBs, mineral-corticoid receptor antago-
nists, and loop diuretics in the presence of congestive symptoms as
evidence of increasing LV filling pressure and/or extensive myocar-
dial fibrosis. Cardiac resynchronization therapy (CRT) has been
employed in the setting systolic dysfunction with concomitant left
bundle branch block (Class IIb, with LOE C recommendation on
CRT), although a survival benefit has not been demonstrated.11
Definitive indications for CRT in end-stage HCM are still lack-
ing and the predictors of response are likely different from those
applied in HF, beginning with the higher LVEF threshold requiring
consideration in HCM.11
Although cardiac transplant is rarely performed in HCM, patients
have an excellent outcome (Class IIa indication for patients with
LVEF <50% and class IIb for patients with LVEF ≥50%, both
with LOE B).11 When disease progression is evident, referral to
transplantation centres should be prompt, as the window of oppor-
tunity may be lost because of rapidly ensuing, refractory pulmonary
hypertension. The use of LV assist devices has been reported in
HCM, but can be challenging because of the small LV dimensions
observed in most end-stage patients (Class IIb with LOE C).11
Management of atrial fibrillation
Atrial fibrillation is the most frequent arrhythmia in HCM, affect-
ing more than 20% of patients, and represents a marker of
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A B
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LGE: 29%
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Figure 3 Cardiac magnetic resonance of a 15-year-old Caucasian female patient with non-obstructive hypertrophic cardiomyopathy,
presenting with severe heart failure symptoms (New York Heart Association class III) despite preserved left ventricular (LV) ejection fraction
(67%). There was evidence of severe pulmonary hypertension, restrictive LV filling pattern and moderate mitral valve insufficiency. She
subsequently required heart transplantation (HTx). Ambulatory medical treatment before admission for HTx were atenolol 100mg once
daily, furosemide 25mg twice daily, acetylsalicylic acid 100mg and ivabradine 5mg once daily (off-label use to control sinus tachycardia). (A)
Extent of late-gadolinium enhancement (LGE—mainly located at the anterior and posterior insertion of the right ventricle free wall—red
arrows) constituting 29% of the LV, compatible with extensive fibrotic replacement. (B) Short axis view showing asymmetric distribution of
hypertrophy; LGE is observed at the site of maximum LV thickness. (C) Four-chamber view showing marked dilatation of the left atrium (LA,
area 39 cm2) and a dysmorphic LV with apically displaced papillary muscle (white arrows) inserted at the level of an ‘amputated’ apex (black
arrow). (D) No evidence of dynamic obstruction at the LV outflow tract (LVOT). RA, right atrium. (Courtesy of Patrizia Pedrotti; Niguarda
Ca’ Granda Hospital, Milan, Italy).
unfavourable prognosis, particularly when associated with LVOTO
and in patients younger than 50 years of age; moreover, the
onset of AF worsens symptoms related to HF.43–45 Follow-
ing onset of paroxysmal AF, long-term antiarrhythmic therapy
is general employed to prevent recurrences (Tables 1 and 2).
Sotalol and, in patients with LVOTO, disopyramide (associated
with beta-blockers), represent reasonable first-line agents while
other Class I agents, such as flecainide or propafenone are
generally avoided owing to concerns with pro-arrhythmic effects .
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..
. and haemodynamic deterioration because of conversion to AF with
rapid ventricular conduction.11 Significant clinical experience with
dronedarone is lacking. When AF relapses in the context of HF
or LVOTO with severe left atrial dilatation, amiodarone represents
the only option for rhythm control. Furthermore, the 2014 ESC
guidelines on HCM recommend the use of amiodarone following
DC cardioversion (class IIa, LOE B).11 Owing to concerns with
long-term toxicity in young patients, the minimum effective dose
should be employed (usually, 200mg five to seven times per week)
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and regular surveillance for thyroid, hepatic, pulmonary, and oph-
thalmic toxicity should be instituted. Symptomatic AF refractory to
optimal pharmacological therapy represents an indication for tran-
scatheter ablation of AF (or surgical maze in obstructive patients
undergoing surgery). However, international experience in HCM
is limited. Patient selection, as high recurrence rates are expected
in older patients with advanced symptoms and marked left atrial
dilatation.46 Thus, AF ablation should be considered early follow-AQ9
ing onset of AF until the arrhythmic substrate remains amenable.
Furthermore, it is important to inform patients that in over 50% a
second procedure is necessary for optimal results and that it may
not be possible to abandon long-term antiarrhythmic therapy.46–48
When maintenance of sinus rhythm is not deemed feasible and
rate control is the only option, beta-blockers (atenolol, nadolol,
metoprolol, or bisoprolol in the presence of a preserved LVEF,
bisoprolol, or carvedilol in the presence of systolic dysfunction) and
verapamil or diltiazem (only with preserved LVEF) are indicated.11
Digoxin should not be used in the setting of classic HCM, but may
be considered in the subgroup with advanced LV dysfunction for
rate control in the setting of chronic AF. Rarely, an ‘ablate and pace’
approach is necessary, usually in end-stage patients.
The onset of AF in HCM patients, even after a single episode,
constitutes an indication to oral anticoagulation irrespective of
other risk factors for embolic stroke such as age or gender. Use
of the CHA2DS2-VASc score is not recommended:
11 in a retro-
spective analysis of 4821 HCM patients, 35.6% subjects with a
CHA2DS2-VASc score of 0 had a thromboembolic event during
the 10-year follow up.49 Furthermore, that analysis demonstrated
that advanced age, presence of AF, previous thromboembolic event,
advanced NYHA class, increased left atrial diameter, presence of
vascular disease, and increased maximal LV wall thickness corre-
lated with risk of thromboembolic events, whereas the use of
vitamin K antagonists was associated with a 54.8% relative risk
reduction in HCM patients with AF.44 Warfarin represents the drug
of choice and should be titrated to maintain an international nor-
malized ratio (INR) between 2.0 and 3.0. However, many young and
active patients show limited compliance with this regimen or refuse
it altogether, while others may have difficulties in maintaining the
INR within the therapeutic range or experience complications.44
Until recently, the less effective alternative of an antiplatelet agent
was offered; however, the introduction of the novel oral antico-
agulants (NOACs), including the direct thrombin inhibitor dabiga-
tran and factor Xa inhibitors rivaroxaban, apixaban, and edoxaban,
is rapidly changing this landscape. While caution is mandatory in
the absence of safety and efficacy data in HCM patients, NOACs
appear a promising alternative to warfarin, and deserve specific
investigation.11
Control of ventricular
arrhythmias
An ICD is considered the only effective strategy for prevention
of arrhythmic SCD in patients with HCM. The ICD is universally
recommended in secondary prevention, as the risk of arrhythmic
relapse after the first episode is as high as 11% per year (Class ..
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.. I LOE B).11,50 Conversely, indications for primary prevention are
hotly debated. A new score has recently been developed by the
ESC,25 by which a high risk is defined as ≥6% at 5 years. The
score is currently being validated in independent cohorts, with
contrasting results.51–53 Conversely, the ACCF/AHA guidelines
favour individual, non-parametric evaluation of major risk factors.12
The issue of the prevention of SCD and arrhythmic risk strat-
ification is beyond the scope of the present review. The issue
remains central to HCM management, and has been the focus of
several articles in the recent literature.15,54 Classic and emerging
risk factors, such as late-gadolinium enhancement and complex
genotypes,55–57 are commonly used to assess risk in individual
patients, with approaches that slightly differ in Europe and the
USA (see the Supplementary material online, Table S1). Irrespec-
tive of any chosen approach, the identification of high-risk patients
remains challenging because of the low arrhythmic event rate, lim-
ited accuracy of risk factors and stochastic nature of SCD.58,59 Even
in high-risk HCM patients, the onset of life-threatening arrhyth-
mias is highly unpredictable, as highlighted by the variable long
time-lapses between ICD implantation and first appropriate inter-
vention. Notably, neither a circadian trend in the onset of ven-
tricular arrhythmias nor a significant correlation with strenuous
exercise has been documented.60 The vast majority of patients
with an ICD will never experience appropriate shocks, but will
be exposed to the long-term complications of the device.50 Fur-
thermore, while paediatric cohorts are considered at highest risk,
older age is associated with a marked reduction in likelihood of
SCD. The risk of SCD is markedly reduced over 65 years of age,
and fewer indications for ICD implantation in primary prevention
exist in this age group. Nevertheless, the option must be evalu-
ated on an individual basis and considered in patients with multiple
risk factors. End-stage progression with systolic dysfunction (arbi-
trarily but consistently defined in the literature by a LVEF <50%)
is associated with a high risk of SCD (around 10% per year) and
therefore considered an indication for ICD implantation in primary
prevention.14,61 However, consideration for an ICD should be given
also to patients with preserved systolic function in the presence of
severe diastolic impairment (restrictive evolution) associated with
NYHA functional class III symptoms.
Several studies show that empirical pharmacological treatment
does not confer optimal protection from SCD (Table 2). Nonethe-
less, amiodarone, sotalol, and beta-blockers reduce the occur-
rence of non-sustained ventricular tachycardia (NSVT).12,62 Thus,
it is likely that a judicious pharmacological approach can be effec-
tive in reducing the arrhythmic burden and lower risk in patients
with HCM, as well as reducing the incidence of appropriate ICD
interventions. In our experience the combination of nadolol with
low-dose amiodarone is well tolerated and effective in reducing
ventricular arrhythmic burden, as documented by ECG Holter
monitoring, potentially contributing to the low incidence of SCD
at our institution in the pre-ICD era (0.5% per year).63
When not to treat
Patients with HCM who are asymptomatic and have no evidence
of arrhythmias or LVOTO at rest or on effort generally do not
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Table 3 drugs that have been employed in different preclinical studies and/or pilot clinical trials as possible
disease-modifying therapies in hypertrophic cardiomyopathy (HCM)
Drug Diltiazem Ranolazine/
eleclazine
Losartan/valsartan Statins Antioxidants
(N-acetyl-cysteine)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Molecular target L-Type Ca channel of
CMs
Late Na current of
CMs
AT1-receptor
blockers on CMs
and myocardial FBs
HMG-CoA reductase Precursor of
glutathione
(antioxidant)
Proposed Mechanism Reduced Ca entry
into the cytosol of
CMs, causing ↓
[Ca]i
Reduced [Na]i and
increased Ca exit
from CMs via
NCX, causing ↓
[Ca]i
Block of AT1
signalling pathway
in CMs
(↓hypertrophy) and
FBs (↓fibrosis)
↓ Rho/Ras in FBs
(↓fibrosis) and in
CMs
(↓hypertrophy); ↓
oxy. stress
↓oxy. stress in FBs AQ10
(↓fibrosis) and CMs
(↓hypertrophy)
Preclinical studies in
AQ11
HCM models
Preventive treatment
in transgenic mice
with R403Q
𝛽-MyHC
mutation70
Study on septal
samples from HCM
patients
(myectomy)70
Losartan in transgenic
mice with
R92Q-TnT
mutation71
Atorvastatin in a
rabbit model with
R403Q MyHC
mutation72
Rabbits with R403Q
MyHC
mutuation;74 mice
with TPM
mutation75
Effects in preclinical
studies
Prevention of
hypertrophy and LV
dysfunction10
Reduction of cellular
arrhythmogenesis,
improved diastolic
function70
Endomyocardial
fibrosis is greatly
reduced after
treatment71
Reduction of
hypertrophy and
increased LV
function72
Reduction of
hypertrophy,
fibrosis74 and
diastolic
dysfunction75
Clinical studies Slowing of phenotype
development in
young mutation
carriers10
Ongoing studies
(RESTYLE-HCM
with ranolazine;
LIBERTY-HCM
with eleclazine)
Losartan in two
studies, 33 and 9.
Reduced LVH in 33,
but no effects on
LVH in 9
Pilot study on 32
patients; no effects
on hypertro-
phy/cardiac
function73
Ongoing Phase 1
study
AQ12
(NCT01537926)
Future perspective Increase the number
of carriers, prolong
follow-up
Prevention of
phenotype
development in
transgenic mice
VANISH study for
prevention of
phenotype in HCM
mutation carriers
None Ongoing Phase 1
study
(NCT01537926)
AT1, Angiotensin II receptor type 1; 𝛽-MyHC, 𝛽-myosin heavy chain; Ca, calcium; CMs, cardiomyocytes; FBs, fibroblasts; HMG-CoA, 3-hydroxy-3-methyl-glutaryl-CoA; LV,
left ventricular; LVH, left ventricular hypertrophy; Na, sodium; NCX, sodium–calcium exchanger; TnT, troponin-T; TPM, tropomyosin. Superscript numbers in the table are
references.
require medical treatment. However, some patients self-reporting
as asymptomatic may subjectively benefit from low doses of
beta-blockers (e.g. bisoprolol 2.5mg once daily), particularly on
effort and after meals. Treatment should be offered as a short
(2–3months) trial, after which each subject may decide whether
to continue. As a rule, it is good to investigate whether the patient
is truly asymptomatic, by performing maximal, symptom-limited
exercise testing and assessing biomarkers over time. Labile
obstruction should also be excluded. In the case of adolescents
and very young adults exercising regularly, heart rate control using
beta-blockers may be considered in order to avoid elevated cardiac
rates on effort, which are associated with lactate production in
HCM hearts, reflecting silent ischaemia.38
Aggressive control of modifiable cardiovascular risk factors is
mandatory in HCM patients, in order to prevent the synergistic
effects of coronary disease, diabetes and hypertension.40 Manage-
ment of hypertension should follow existing guidelines.64 Although
the introduction of vasodilators should be cautious and gradual,
because of potential worsening of resting or labile LVOTO, recent
trials have shown that ARBs are safe and generally tolerated in .
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. HCM patients.9,33 Finally, patients with obstructive HCM have a
significant prevalence of obstructive sleep apnoea syndrome; this
may exacerbate symptoms and arrhythmias and should be specifi-
cally sought and managed.65 Advice regarding appropriate lifestyle
maybe extremely useful in reducing symptoms and risk in HCM
patients, and may suffice in milder forms of the disease in which
pharmacological therapy is not warranted. There is general consen-
sus that patients should abstain from competitive sports, as well as
from strenuous and protracted physical activities, which can rep-
resent a trigger for arrhythmias and SCD (Class I, LOE C in the
2014 ESC guidelines).11 Conditions that reduce circulating blood
volume should be avoided, to prevent worsening of LVOTO.66
Novel perspectives
A surge in pharmacological research on HCM has followed the
identification of novel therapeutic targets, and holds promise for a
rapid change in clinical management of this disease. Several molec-
ular mechanisms and disease pathways, stemming from the genetic
background of HCM, represent appealing therapeutic targets, and
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Table 4 Ongoing and completed randomized clinical trial assessing efficacy and safety of medical agents in patients
with hypertrophic cardiomyopathy (HCT) since 2010
First Author or
Name of the study
Drug on evaluation Endpoint of
the study
Number of
patients
Results Year of publication
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abozguia et al.68 Perhexiline 100mg vs.
placebo
Efficacy on diastolic
function and
exercise capacity
46 patients with
non-obstructive
symptomatic HCM
The metabolic
modulator
perhexiline
improved diastolic
function and
increased peak
oxygen uptake
2010
Shimada et al.31 Losartan 50mg bid vs.
placebo
Effects on LVH and
fibrosis
20 patients with
non-obstructive
HCM
attenuation of
progression of LVH
and fibrosis with
losartan
2013
INHERIT trial9 Losartan 100mg vs.
placebo
Effects on LVH and
fibrosis
124 patients with
obstructive or
non-obstructive
HCM
Losartan did not
reduce LVH.
Treatment with
losartan was safe
2015
Ho et al.10 Diltiazem 360mg/die
vs. placebo
Safety, feasibility and
effect of diltiazem
as
disease-modifying
therapy
38 sarcomere
mutation carriers
without LVH
Diltiazem improved
early LV
remodelling
2015
– Perhexiline 100mg
(sponsor Heart
Metabolics Ltd) vs.
placebo
Hierarchical
classification of
outcome variable
and change in
maximum oxygen
consumption after
6months
320 patients with
HCM and
moderate to severe
HF
Phase III Starting March 2016
(NCT02431221)
RESTYLE-HCM† Ranolazine Change in maximum
oxygen
consumption at
CPET
80 patients Phase II/III Ongoing—completed
recruitment
LIBERTY-HCM GS-6615 (sponsor:
Gilead Sciences) vs.
placebo
Safety/efficacy study
on exercise
capacity in pts with
symptomatic
180 patients with
HCM
Phase II/III evaluation
of change in peak
oxygen uptake
Ongoing—recruiting
patients
NCT02291237
VANISH (New
England Research
Institute, USA)
Valsartan up to
160mg vs. placebo
Composite endpoint
of functional
capacity, amount of
myocardial fibrosis
and other
parameters after
2 years
150 patients HCM
with NYHA I–II
and mutation
carriers without
LVH
Phase II Ongoing–recruiting
patients
(NCT01912534)
University of Texas,
Health Science
Centre, Houston,
USA
N-acetylcystein
600/1200mg vs.
placebo
Regression of indices
of cardiac LVH
after 3 years
75 patients with HCM
and preserved
systolic function
Phase I Ongoing—recruiting
patients
(NCT01537926)
AQ13
CPET, cardiopulmonary exercise test; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LVH, left ventricular hypertrophy; NYHA, New York Heart Association.
*With updated data on clinicaltrials.gov (key word: ‘hypertrophic cardiomyopathy’, selected on 116 studies) and pubmed.org (Key words: ‘hypertrophic cardiomyopathy’ AND
‘clinical trials’ from 2010: 143 results). No updated data were available regarding clinical trials testing the efficacy of pirfenidone 400mg b.i.d. (completed recruitment in 2003,
NCT00011076) and atorvastatin 80mg (completed recruitment in 2010, NCT00317967). RHYME study is a non-randomized study registered in clinicaltrials.gov aimed to
test efficacy of ranolazine in reducing angina symptoms after 60 days in 20 patients (NCT01721967).
†Study not registered in clinicaltrials.gov.
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have been reviewed by Ashrafian et al.67 Indeed, based on sound
translational research, a number of agents have already found their
way to clinical testing. Perhexiline, a metabolic modulator that
inhibits the metabolism of free fatty acids and enhances carbohy-
drate utilization by cardiomyocytes, has been employed with the
aim of normalizing energy homeostasis in HCM. In a randomized,
double-blind placebo-controlled trial, perhexiline has shown the
capacity to improve the ratio of myocardial phosphocreatine to
adenosine triphosphate in the myocardium, resulting in improved
diastolic function and exercise capacity.68 A randomized, pivotal
Phase 3 trial of 350 patients evaluating perhexiline for the treat-
ment of moderate-to-severe HCM has recently been announced
(http://www.heartmetabolics.com/news/2015/news-041515.html).
However, concerns exist regarding the safety profile of the
drug, following reports of hepatotoxicity in predisposed indi-
viduals, and the drug requires long-term monitoring of plasma
levels.69
Recently, human HCM cardiomyocytes have been shown exhibit
marked electrophysiological remodelling leading to abnormal intra-
cellular calcium handling, enhanced arrhythmogenesis, abnormal
diastolic function, and excessive energy expenditure. These defects
are selectively reversed in vitro by the late sodium current inhibitor
ranolazine.70 Thus, targeting this single molecular mechanism
has the potential to counter several key components of the
HCM pathophysiology, including diastolic dysfunction, microvas-
cular dysfunction, arrhythmogenesis and, by virtue of a mild
negative inotropic effects, dynamic outflow obstruction.70 These
data provided a rationale for the recently completed multicentre,
double-blind, placebo-controlled pilot study, testing the efficacy of
ranolazine on exercise tolerance in symptomatic HCM patients
(RESTYLE-HCM; EUDRA-CT 2011-004507-20). While results ofAQ14
RESTYLE-HCM are awaited a phase II/III trial, the LIBERTY-HCM
study, has already started testing the efficacy of a new, more spe-
cific and potent late sodium current inhibitor, eleclazine (Clinical-
trials.gov NCT02291237). LIBERTY-HCM will test the hypothesis
that, compared with placebo, eleclazine improves exercise capacity
as measured by peak oxygen consumption (VO2) during cardiopul-
monary exercise testing in patients with symptomatic HCM from
over 40 centres in Europe and the USA. Additional drugs that
have been employed in different preclinical studies and/or pilot
clinical trials as possible disease-modifying therapies in HCM are
listed in Tables 3 and 4 and include angiotensin II receptor type
1 (AT1)-receptor blockers losartan and valsartan,9,57,71 statins,72,73
and N-acetyl-cysteine.74,75
Finally, a ‘precision medicine’ approach is emerging based on
the hypothesis that, in selected genetic subsets, HCM is triggered
by a hypercontractile state caused by reduced inhibitory effect
of the myosin-binding protein C on the cardiac myosin head. By
selectively reducing the affinity of myosin for actin, the downstream
consequences of sarcomere mutations might be countered in HCM
patients, including prevention of phenotype development in the
early stages of the disease.76 Two phase I studies have been recently
launched to assess the effects of MYK-461 (Myokardia, South
San Francisco, CA, USA), the first allosteric inhibitor of cardiac
myosin tested in man, in patients with HCM (Clinicaltrials.gov
NCT02329184 and NCT02356289). ..
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.. Conclusions
Hypertrophic cardiomyopathy largely remains an orphan disease. In
the near future, however, the debut of evidence-based approaches
to HCM is likely to revolutionize its management by provid-
ing agents targeting disease-specific substrates. Until then, judi-
cious use of the available pharmacological armamentarium may
already provide sufficient control of the most common clinical
manifestations and complications, allowing normal longevity in the
majority of patients. Serial assessment and early identification of
disease progression is key for timely implementation of available
therapies.
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